Introduction {#sec1-1}
============

Functions of the immune system against the tumor cells are divided into three parts. First, the immune system suppresses the viral infection to protect the host from virus-induced tumors. Second, it causes the post-inflammatory environment to prevent the carcinogenicity. And third, it identifies the tumor cells and eliminates them.\[[@ref1]\] The latest function was introduced in 1950s as immune-surveillance hypothesis which explains how immune system can eliminate the early stage tumor.\[[@ref2][@ref3]\] This hypothesis was the basis for the development of models to predict the tumor-immune system interactions using mathematical equations. Using this mathematical models, researchers can overcome the lack of knowledge about cancer and its interaction with immune system.\[[@ref4][@ref5]\]

The CD8+ T-cells are one type of immune cells which play principal role in anti-tumor response of immune system. Previous studies demonstrated that, in nude mice with CD8+ shortage, the immune system was not able to effectively inhibit the tumor cells.\[[@ref6]\] The CD8+ cells have several pathways to detect and to eliminate the tumor cells.\[[@ref7]\]

When immune system confronts a stranger, it suppresses itself to prevent perishing the host cells. It is possible that this suppression is mediated by cells such as regulatory T-cells (Treg) and myeloid-derived suppressor cells (MDSCs), or proteins such as transforming growth factor-beta (TGF-β).\[[@ref8]\] Tumor cells use these approaches for immune evasion which may consequently result in tumor development. Therefore, elimination of immune suppressor factors such as MDSCs could be an effective approach to reinforce the immune system.

The low-dose 5-fluorouracil (5-FU) is able to selectively eliminate the MDSCs in tumor microenvironment.\[[@ref9]\] In addition, many studies have investigated effects of other factors such as all-trans-retinoic acid (ATRA),\[[@ref10]\] gemcitabine,\[[@ref11]\] ATRA and anti-CD25 antibody,\[[@ref12]\] nitroaspirin derivative\[[@ref13]\] and cisplatin\[[@ref14]\] on MDSCs depletion.\[[@ref15]\] All these factors resulted in better tumor prognosis.

Many studies have mathematically modeled the tumor-immune system interaction, and their results have provided insight about the activity of the immune system against the tumor cells. Many of these models investigated the spatial manner of tumor microenvironment based on partial differential equation or cellular automata.\[[@ref16][@ref17][@ref18][@ref19][@ref20]\] Some studies only investigated the population of cells using temporal models. These models are based on ordinary differential equation (ODE) or agent-based modeling (ABM).\[[@ref5][@ref21]\] Primary temporal models investigated the interactions between tumor cells and effector cells such as natural killer cells (NK cells) and cytotoxic T-lymphocytes (CTLs).\[[@ref22][@ref23]\] Later studies, however, added cytokines such as TGF-β and interleukin-2 to this interaction\[[@ref24]\] and investigated the immunotherapy.\[[@ref25][@ref26][@ref27][@ref28]\] These studies were mainly based on ODE and only few of them considered ABM.\[[@ref5][@ref29]\]

To control cancer, there are various therapeutic approaches such as chemotherapy,\[[@ref19][@ref30]\] radiotherapy,\[[@ref31]\] bacteria-therapy,\[[@ref32]\] combination therapy\[[@ref33]\] and immune-therapy.\[[@ref34]\] Although immune-therapy seems to be an effective approach for eliminating the tumor, however, presence of postinflammatory agents such as MDSCs may decrease positive therapeutic effects.\[[@ref35]\] Hence, depletion of MDSCs would lead to more beneficial treatment.

ABM can consider properties of each cell and its memory.\[[@ref36][@ref37]\] An agent-based model of tumor-immune system interactions which contains agents and environment, each component having active behavior is considered as agent, and on the other hand, the components which have passive behavior are the environment.

To the authors' knowledge, no model has been developed to investigate the effect of immune suppressors such as MDSCs. Therefore, this study aimed to model and to simulate the effect of MDSCs on tumor-immune system interactions. In addition, since recent studies have demonstrated that the low dose of 5-FU can annihilate the effect of MDSCs on immune system suppression,\[[@ref35]\] therefore, the effect of one and multiple dose of 5-FU were also evaluated in this model.

Materials and Methods {#sec1-2}
=====================

Immunologic definitions {#sec2-1}
-----------------------

In this model, three components will be considered including tumor cells, effector cells (CTLs) and MDSCs. Actions of these components, based on which the model was developed, were defined as below;

Action of tumor cells:

Proliferation: Tumor cells may proliferate based on their populationProliferating the CTLs: The antigen presentation of tumor cells can cause the CTLs proliferationRecruitment of MDSCs: the post-inflammatory condition in tumor microenvironment can cause the MDSCs recruitment.\[[@ref15][@ref38][@ref39]\]

CTLs have two following actions:

Killing the tumor cells: The CTLs can cause the tumor cell cytotoxicityApoptosis: CTLs will be dying as programmed death.

MDSCs also show two actions:

Inhibiting the CTLs Proliferation: MDSCs as immune suppressor cells can inhibit the proliferation of CTLsApoptosis: MDSCs will be dying as programmed death.

Agent based model {#sec2-2}
-----------------

As mentioned above, the agent-based model contains three components each of which has its own action. Each action was modeled as a mathematical equation. First, tumor cells proliferate as Eq. 1.

*T*~p~(*n*) = aT(*n*) (1 -- bT\[*n*\])      (1)

In Eq. 1, *T*~p~(n) shows the number of proliferating tumor cells at *n*^th^ time point, *T*(n) is number of tumor cells, a is proliferation rate and b is number of tumor cells limitation.

The second action of tumor cells is CTLs proliferating, which was modeled as Eq. 2.

*E*~p~(*n*) = mT(*n*)      (2)

Where, *E*~p~(*n*) is number of proliferating CTLs at *n*^th^ and m is CTLs proliferation rate.

The third action of tumor cells is MDSCs recruitment, which can be modeled as Eq. 3.
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*M*~r~(n) is number of recruiting MDSCs at *n*^th^ time point, x is the rate of MDSCs recruitment and y is limitation factor.

There are also two actions for CTLs. First, they kill the tumor cells with a predefined cytotoxicity modeled as Eq. 4.

*T*~k~(*n*) = *j*T(*n*) *E*(*n*)      (4)

In this equation, *T*~k~(*n*), *j* and *E*(*n*) demonstrate the number of killed tumor cells, cytotoxicity of CTLs and number of CTLs, respectively. CTLs also show that may be dying by apoptosis as Eq. 5.

*E*~d~(*n*) = *dE*(*n*)      (5)

In this equation, *E*~d~(*n*) indicates the dead CTLs at *n*^th^ time point and *d* represents the CTL\'s apoptosis rate.

The final component of this model is MDSCs, which have two actions of inhibition of the CTL\'s proliferation and apoptosis and was modeled as Eqs. 6 and 7.
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*M*~d~(*n*) = μM(*n*)      (7)

*E*~i~(*n*) is CTL\'s proliferation inhibition factor, *M*(*n*) is the number of MDSCs at *n*^th^ time point, *M*~d~(*n*) indicates number of died MDSCs at *n*^th^ time point and μ is MDSC\'s apoptosis rate.

Eqs. 8-10 represent the overall equations of this model which is also depicted in [Figure 1](#F1){ref-type="fig"}.

![Graphical view of defined agent-based model](JMSS-9-15-g003){#F1}

*T* (*n* + 1) = *T*(*n*) + *T*~p~(*n*) -- *T*~k~(*n*)      (8)

*E* (*n* + 1) = *E*(*n*) + *E*~p~(*n*) *E*~i~(*n*) -- *E*~d~(*n*)      (9)

*M* (*n* + 1) = *M*(*n*) + *M*~r~(*n*) -- *M*~d~(*n*)      (10)

Another purpose of this study was to investigate the effect of MDSCs depletion by 5-FU on response of immune system to tumor cells. To this end, effect of 5-FU on MDSCs depletion was modeled. Effect of 5-FU on leukocytes was investigated in\[[@ref40]\] and also demonstrated in [Figure 2](#F2){ref-type="fig"}. In this study, this effect of 5-FU on leukocyte was generalized to MDSCs and estimated by Rayleigh function as Eq. 11.

![The leukocyte depletion impact of 5-fluorouracil](JMSS-9-15-g004){#F2}
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*I~5-FU~* indicates the impact of 5-FU on MDSC depletion, ε demonstrates the dosage power of 5FU and σ shows attenuation of 5-FU\'s impact through time.

Results {#sec1-3}
=======

Simulation of tumor-immune system model will be described in this section. First, model was simulated without any intervention and then effects of 5-FU were considered. For model simulation, the values of coefficients were identified as [Table 1](#T1){ref-type="table"}. As other studies Allahverdy *et al*.,\[[@ref29]\] used a constant rate as proliferation or recruitment, but in our study, this rate has been impressed by the number of MDSC\'s. Therefore, this model can be valid by this factors (cause all factors are same and recruitment rate just affected by the number of MDSC\'s).

###### 

The values of coefficients of tumor-immune system model

  Coefficient   Value
  ------------- --------
  a             1.05
  b             0.0022
  m             0.03
  d             0.12
  g             0.74
  x             0.33
  y             0.04
  j             0.015
  µ             0.03
  ε             8.2
  σ             3

Initially, stability analysis of the model was conducted. As the effect of MDSCs population was considered in this study, for this aim, all coefficients were considered as constant, illustrated in [Table 1](#T1){ref-type="table"}, and "x" was the variable coefficient which has effective role on the stability analysis.

To start, fix points of Eqs. 8-10 were calculated as below:

*T*~p~(*n*) -- *T*~k~(*n*) = 0      (12)

*E*~p~(*n*) *E*~i~(*n*) -- *E*~d~(*n*) = 0      (13)

*M*~r~(*n*) -- *M*~d~(*n*) = 0      (14)

By insertion of Eqs. 1-7 in Eqs. 12-14, the fix points were achieved.

Then, to evaluate the stability of the model, the Jacobian matrix of Eqs. 8-10 were computed as below:
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The attribute of eigenvalues of this matrix defines stability of the model. There are three types of stability including node, repellor, and saddle. If all eigenvalues have negative real part, the fix point will be node. If all eigenvalues have positive real part, the fixpoint is repellor and whether one or two eigenvalues have positive real part, the fixpoint will be saddle. Nonzero imaginary part will also define the spiral manner for each type of fixpoint. To evaluate the type of fix point, the value of "x" was set at 0.01--2 and then real and imaginary parts of eigenvalues evaluated. Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} depict the real and imaginary parts of eigenvalues, respectively.

![Real part of eigenvalues versus change "x"](JMSS-9-15-g007){#F3}

![Imaginary part of eigenvalues versus change "x"](JMSS-9-15-g008){#F4}

As [Figure 3](#F3){ref-type="fig"} demonstrates, all the eigenvalues have negative real part. Therefore, the fixpoint is node and in low "x" values the imaginary part of eigenvalues are nonzero and the spiral manner can be illustrated by fixpoint.

To illustrate the result of model\'s simulation, the two-dimensional view of tumor microenvironment and the number of cells in the tumor microenvironment over 51 days has been demonstrated in [Figure 3](#F3){ref-type="fig"}. In this simulated model, the dark blue pixels are healthy tissue, live tumor cells, died tumor cells, CTLs (effector cells), and MDSCs have been marked in dark blue, bright blue, red and orange pixels, respectively. As depicted in [Figure 5](#F5){ref-type="fig"}, through time MDSCs infiltrate the tumor microenvironmet and suppress the effector cells which consequently make the microenvironment suitable for tumor growth.

![Tumor microenvironment over the time without any intervention](JMSS-9-15-g009){#F5}

As illustrated in [Figure 6](#F6){ref-type="fig"}, the number of effector cells tends to follow the number of tumor cells. However, this is prevented by the recruitment of MDSCs and as a result the tumor cells will escape the immune system.

![Number of cells in tumor microenvironment without any intervention](JMSS-9-15-g010){#F6}

According to [Figure 6](#F6){ref-type="fig"}, at the beginning, effector cells tend to grow. However, more number of MDSCs would inhibit the increment of effector cells, and consequently, the tumor cells will grow.

For the next step and on day 5^th^, the one dose of 5-FU was administered which was simulated by Eq. 11. The MDSCs depletion effect of 5-FU is illustrated in [Figure 7](#F7){ref-type="fig"}.

![Myeloid-derived suppressor cells depletion with one dose injection of 5-fluorouracil](JMSS-9-15-g011){#F7}

As illustrated, 5-FU had a considerable effect on MDSCs on day 7^th^ and this effect lasted until day 15^th^. To investigate the effect of 5-FU injection on tumor microenvironment, this effect contributed by the model of tumor-immune system interaction. As [Figure 8](#F8){ref-type="fig"} demonstrates, on day 21^th^, the tumor size reduced. However, after that and through time, tumor size increased again. Which means one dose of 5-FU is not sufficient enough for sustainable effects.

![Tumor microenvironment modification by time pass with one dose injection of 5-fluorouracil](JMSS-9-15-g012){#F8}

Looking at [Figure 9](#F9){ref-type="fig"}, number of MDSCs decreased on day 7^th^ which in turn resulted in increase in number of effector cells and decrease in number of live tumor cells. However, this was a cross-sectional effect, and the number of MDSCs increased through time and tumor cells escaped the immune system.

![The effect of one dose injection of 5-fluorouracil on number of cells in tumor microenvironment](JMSS-9-15-g013){#F9}

As the third step, this model has been contributed by two dose injection of 5-FU. The first injection was on day 5^th^ and the second one was on day 10^th^. [Figure 10](#F10){ref-type="fig"} demonstrates the effect of these injections on the tumor microenvironemt. According to figure, between day 21^th^ and 31^th^, tumor decreased in size. However, on day 41^th^, the tumor grew again which again means two dose of 5-FU is not a effective yet.

![Tumor microenvironment modification by time pass with two dose injection of 5-fluorouracil](JMSS-9-15-g014){#F10}

Based on [Figure 11](#F11){ref-type="fig"}, which depicts the number of each cells in the tumor microenvironemt, the immune system initially overcomes tumor cells, however, the size of tumor cells increased again on day 41^th^.

![The effect of two dose injection of 5-fluorouracil on number of cells in tumor microenvironment](JMSS-9-15-g015){#F11}

In the next phase, the third dose of 5-FU was administered. To avoid chemotherapy effect of 5-FU on tumor cells, this injection was simulated on day 20^th^. Change of tumor microenvironment through time has been depicted in [Figure 12](#F12){ref-type="fig"} which indicates third dose of 5-FU had long-lasting suppressing effects on size of tumor cells that would make this intervention effective.

![Tumor microenvironment modification by time pass with three dose injection of 5-fluorouracil](JMSS-9-15-g016){#F12}

[Figure 13](#F13){ref-type="fig"} shows the change of each cell over the time. As it can be seen, the number of tumor cells reached and remained zero and immune system overcomes the tumor cells.

![The effect of three dose injection of 5-fluorouracil on number of cells in tumor microenvironment](JMSS-9-15-g017){#F13}

Discussion {#sec1-4}
==========

Mathematical model of tumor-immune system interaction, which is time and cost-effective, is a useful method to gain insight about the interaction between components of the immune system and tumor cells. In addition, to investigate the effectiveness of interventions, application of these models might be beneficial. In this study, a new agent-based model was introduced that was based on interaction between tumor cells and effector cells. The effect of MDSCs, which suppress the proliferation of effector cells and cause the increment in number of tumor cells, was also considered in this model. To evaluate the effectiveness of intervention, the impact of low-dose 5-FU of MDSCs depletion was also simulated.

Simulation of this model was conducted in four steps. At the first step, simulation was done without any intervention. The results of this simulation showed recruitment of MDSCs prevents the increment of effector cells and creates a situation which allows the tumor cells to escape. At the second step, one dose of 5-FU was considered as an intervention. According to finding, 5-FU initially result in MDSCs depletion and decrement of the number of MDSCs in return led to increment of effector cells and consequently the decrement of the number of tumor cells. However, this effect was temporary and through time, the number of MDSC increased again. It was interpreted that the additional dose of 5-FU was required for more long-lasting effects. Hence, for the next step, the second dose of 5-FU was considered. As expected, this results in decrease in size of tumor cells which was transient again. At the final step, third dose of 5-FU was simulated this time all the tumor cells were eliminated and the immune system overcame the tumor cells. This finding was consistent with the results of the other similar study.\[[@ref35]\] The first limitation of this study is low dose of 5-FU. Since 5-FU is a drug used in chemotherapy It is possible to act as a anti-tumor substance rather than MDSC\'s depletion. Number of 5-FU injection is the other limitation. If the dose of 5-FU precisely determined as low, but the number of injection increased or the injection interval decreased, the effect of injections may synergy and subsequently act as chemotherapy drug. Finally, this model only investigated a presumptive tumor. For further examination, this model must be retrofitted for every tumor cell lines like sarcoma, glioblastoma, melanoma and gastric cancer.

The immune system can fight the tumor cells in many pathways, therefore, adding more components of the immune system to this model may be useful to gain more insight about the realistic behavior of tumor cells against the immune system. Moreover, tumor cells may have more strategies to escape the immune system and increasing their maintenance such as angiogenesis which can be contributed in this model.
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